Mozolieva 20 mg Injection 1's

Mozolieva 20 mg Injection 1's belongs to the class of hemopoietic stem cell mobilizer. It is used in the treatment of Non-Hodgkin’s Disease (a blood cancer that affects your lymph system) and multiple myeloma (a type of cancer that affects the plasma cells of the bone marrow) in combination with granulocyte-colony stimulating factor (G-CSF).

Mozolieva 20 mg Injection 1's contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibits the binding of its cognate ligand CXCL12.

Mozolieva 20 mg Injection 1's may cause certain side effects, such as nausea, vomiting, headache, dizziness, diarrhoea, flatulence, fatigue, and pain at the site of injection. These side effects do not require medical attention and gradually resolve over time. A trained healthcare professional will administer it. Do not self-administer.

Avoid taking it and inform your doctor if you are allergic to Mozolieva 20 mg Injection 1's or its components. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders or respiratory conditions. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued during the treatment.

Mozolieva 20 mg Injection 1's is used in the treatment of Multiple Myeloma and Non-Hodgkin’s Disease. The detailed uses of Mozolieva 20 mg Injection 1's are as follows:

• Stem cell mobilization: Mozolieva 20 mg Injection 1's is used in combination with granulocyte-colony stimulating factor (G-CSF) to help the bone marrow release hematopoietic stem cells into the bloodstream. These cells are then collected for autologous stem cell transplantation, a procedure often used in cancer treatment.
• Treatment of certain cancers: Mozolieva 20 mg Injection 1's is indicated for patients with non-Hodgkin’s lymphoma and multiple myeloma who are undergoing stem cell transplantation. By increasing the number of stem cells in the blood, it improves the success rate of the transplant.

• Follow your doctor’s instructions on the dosage and timing of this medication. Typically, it is injected once a day, 11 hours prior to blood cell removal, for up to 4 days in a row.
• Mozolieva 20 mg Injection 1's will be administered under the skin by a doctor or nurse in a medical facility.
• Do not self-administer.

Mozolieva 20 mg Injection 1's contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibiting its cognate ligand CXCL12 binding. This mobilizes hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in cancer patients.

Mozolieva 20 mg Injection 1's should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders, anaemia, or respiratory conditions. Mozolieva 20 mg Injection 1's may cause the potential for tumor cell mobilization in leukemia patients, haematological effects, and splenic rupture in some patients. Hence, careful monitoring should be done during the entire treatment. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued in nursing mothers during the treatment. Mozolieva 20 mg Injection 1's should be avoided in children as safety is not established.